HGF/c-MET targeted the rapeutics: Novel strategies for cancer medicine

Current Drug Targets

Volumn 12, Issue 14, 2011, Pages 2045-2058

  Yap, Timothy A ^a,b   Sandhu, Shahneen K ^a,b   Alam, Salma M ^a,b   de Bono, Johann S ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

ARQ 197; c MET; Clinical trials; Hepatocyte growth factor; MetMAb; Monoclonal antibodies; Personalized medicine; Small molecule inhibitors; Targeted therapeutics

Indexed keywords

AMG 208; AMUVATINIB; CABOZANTINIB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FORETINIB; GANITUMAB; GEFITINIB; GEMCITABINE; IMATINIB; MESENCHYMAL EPITHELIAL TRANSITION FACTOR; MGCD 265; MITOXANTRONE; MK 2461; MONOCLONAL ANTIBODY; PACLITAXEL; PEMETREXED; PF 04217903; PLACEBO; PROTEIN TYROSINE KINASE; RILOTUMUMAB; SCATTER FACTOR; SORAFENIB; TEMOZOLOMIDE; TIVANTINIB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; CANCER GROWTH; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GENE OVEREXPRESSION; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPIGMENTATION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PROTEIN FUNCTION; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THYROID CANCER; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84855860082     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798829348     Document Type: Review

References (134)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10(8): 789-99.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2(8): 563-72.
3. Shook D, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 2003; 120(11): 1351-83.
4. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2(4): 289-300.
5. Comoglio PM, Boccaccio C. Scatter factors and invasive growth. Semin Cancer Biol 2001; 11(2): 153-65.
6. Yanagida H, Kaibori M, Hijikawa T, Kwon AH, Kamiyama Y, Okumura T. Administration of rhHGF-activator via portal vein stimulates the regeneration of cirrhotic liver after partial hepatectomy in rats. J Surg Res 2006; 130(1): 38-44.
7. Chmielowiec J, Borowiak M, Morkel M, et al. c-MET is essential for wound healing in the skin. J Cell Biol 2007; 177(1): 151-62.
8. Neuss S, Becher E, Woltje M, Tietze L, Jahnen-Dechent W. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 2004; 22(3): 405-14.
9. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7(6): 504-16.
10. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005; 15(1): 49-51.
11. Ma PC, Maulik G, Christensen J, Salgia R. c-MET: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22(4): 309-25.
12. Stellrecht CM, Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 2009; 280(1): 1-14.
13. Mazzone M, Comoglio PM. The Met pathway: master switch and drug target in cancer progression. FASEB J 2006; 20(10): 1611-21.
14. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 1994; 9(1): 49-57.
15. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77(2): 261-71.
16. Naldini L, Vigna E, Ferracini R, et al. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol 1991; 11(4): 1793-803.
17. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996; 384(6605): 173-6.
18. Boccaccio C, Ando M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998; 391(6664): 285-8.
19. Schaeper U, Gehring NH, Fuchs KP, Sachs M, Kempkes B, Birchmeier W. Coupling of Gab1 to c-MET, Grb2, and Shp2 mediates biological responses. J Cell Biol 2000; 149(7): 1419-32.
20. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008; 27(1): 85-94.
21. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006; 6(8): 637-45.
22. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001; 98(1): 247-52.
23. Fan S, Ma YX, Wang JA, et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene 2000; 19(18): 2212-23.
24. Bertotti A, Comoglio PM. Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends Biochem Sci 2003; 28(10): 527-33.
25. Pelicci G, Giordano S, Zhen Z, et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 1995; 10(8): 1631-8.
26. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002; 16(23): 3074-86.
27. van der Voort R, Taher TE, Wielenga VJ, et al. Heparan sulfatemodified CD44 promotes hepatocyte growth factor/scatter factorinduced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem 1999; 274(10): 6499-506.
28. Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001; 107(5): 643-54.
29. Giordano S, Corso S, Conrotto P, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002; 4(9): 720-4.
30. Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 1993; 121(1): 145-54.
31. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995; 373(6516): 699-702.
32. Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999; 29(3): 209-48.
33. Gille J, Khalik M, Konig V, Kaufmann R. Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. J Invest Dermatol 1998 Dec; 111(6): 1160-5.
34. Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001; 158(3): 1111-20.
35. Galimi F, Cottone E, Vigna E, et al. Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol 2001; 166(2): 1241-7.
36. Gerritsen ME, Tomlinson JE, Zlot C, Ziman M, Hwang S. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 2003; 140(4): 595-610.
37. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15(7): 2207-14.
38. Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 2002; 62(18): 5126-8.
39. Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of betacatenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002; 62(7): 2064-71.
40. Park M, Dean M, Cooper CS, et al. Mechanism of met oncogene activation. Cell 1986; 45(6): 895-904.
41. Ivan M, Bond JA, Prat M, Comoglio PM, Wynford-Thomas D. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997; 14(20): 2417-23.
42. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3(4): 347-61.
43. Ferracini R, Di Renzo MF, Scotlandi K, et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995; 10(4): 739-49.
44. Ayhan A, Ertunc D, Tok EC, Ayhan A. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer 2005; 15(4): 618-23.
45. Gao L, Feng Y, Bowers R, et al. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res 2006; 66(16): 7880-8.
46. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004; 10(1 Pt 1): 202-11.
47. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 1997; 74(3): 301-9.
48. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995; 147(2): 386-96.
49. Morello S, Olivero M, Aimetti M, et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol 2001; 189(3): 285-90.
50. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995; 1(2): 147-54.
51. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 2005; 7(1): 75-84.
52. Seruca R, Suijkerbuijk RF, Gartner F, et al. Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer. Cancer Genet Cytogenet 1995; 82(2): 140-5.
53. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr Rev 1994; 15(2): 202-32.
54. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human nonsmall-cell lung carcinomas. Br J Cancer 1996; 74(12): 1862-8.
55. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16(1): 68-73.
56. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18(14): 2343-50.
57. Lindor NM, Dechet CB, Greene MH, et al. Papillary renal cell carcinoma: analysis of germline mutations in the MET protooncogene in a clinic-based population. Genet Test 2001; 5(2): 101-6.
58. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 1997; 94(21): 11445-50.
59. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006; 66(1): 283-9.
60. Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006; 66(1): 352-61.
61. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000; 19(12): 1547-55.
62. Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999; 59(2): 307-10.
63. Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000; 19(43): 4947-53.
64. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009; 10(7): 709-17.
65. Bellusci S, Moens G, Gaudino G, et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 1994; 9(4): 1091-9.
66. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3T3 cells induced by Methepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994; 91(11): 4731-5.
67. Corso S, Migliore C, Ghiso E, De Rosa G, Comoglio PM, Giordano S. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 2008; 27(5): 684-93.
68. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997; 94(2): 701-6.
69. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999; 9(1): 15-21.
70. Stella MC, Trusolino L, Pennacchietti S, Comoglio PM. Negative feedback regulation of Met-dependent invasive growth by Notch. Mol Cell Biol 2005; 25(10): 3982-96.
71. Tu H, Zhou Z, Liang Q, et al. CXCR4 and SDF-1 production are stimulated by hepatocyte growth factor and promote glioma cell invasion. Onkologie 2009; 32(6): 331-6.
72. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci 2005; 96(6): 317-22.
73. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000; 19(27): 3041-9.
74. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000; 275(12): 8806-11.
75. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316(5827): 1039-43.
76. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104(52): 20932-7.
77. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225(1): 1-26.
78. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66(3): 1721-9.
79. Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006; 12(4): 1292-8.
80. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997; 420(1): 1-6.
81. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60(23): 6737-43.
82. Athauda G, Giubellino A, Coleman JA, et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 2006; 12(14 Pt 1): 4154-62.
83. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004; 6(1): 61-73.
84. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I Vol 25, No 18S (Suppl), 2007: 4000
85. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-92.
86. Barni S, Petrelli F, Cabiddu M, Cazzaniga ME, Cremonesi M. From the trastuzumab era to new target therapies: beyond revolution. Ann Oncol 2007; 18(Suppl 6): vi1-4.
87. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed antic-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12(20 Pt 1): 6144-52.
88. Merchant M, Zheng Z, Romero M, et al. One-armed 5D5 (OA5D5) is a potent humanized HGF-blocking anti-c-Met monovalent antibody that inhibits HGF-dependent activity in vitro and demonstrates anti-tumor efficacy in vivo. AACR Meeting Abstracts 2007; LB-372.
89. Petrelli A, Circosta P, Granziero L, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor downregulation and hampers biological activity. Proc Natl Acad Sci USA 2006; 103(13): 5090-5.
90. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99(6): 1928-37.
91. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008; 26(34): 5589-95.
92. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-34.
93. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005; 11(6): 2312-9.
94. Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep 2007; 9(2): 102-8.
95. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002; 21(32): 4885-93.
96. Berthou S, Aebersold DM, Schmidt LS, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004; 23(31): 5387-93.
97. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103(7): 2316-21.
98. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67(9): 4408-17.
99. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6(12 Pt 1): 3314-22.
100. Kwak E, Camidge D, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009; 27(15S): abstr 3509.
101. Jeay S, Munshi N, Hill J, et al. ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells. American Association for Cancer Research Annual Meeting: Proceedings 2007; Los Angeles, CA Philadelphia (PA): AACR; 2007 Abstract 2369.
102. Munshi N, Jeay S, Hill J, et al. ARQ 197, a highly selective small molecule inhibitor of c-Met, inhibits invasive and metastatic growth of cancer cells. American Association for Cancer Research Annual Meeting: Proceedings 2007; Los Angeles, CA Philadelphia (PA): AACR; 2007 Abstract 2367.
103. Mekhail T, Rich T, Rosen L, et al. Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors. J Clin Oncol 2009; 27(15S); abstr 3548.
104. Yap T, Frentzas S, Tunariu N, et al. Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition. J Clin Oncol 2009; 27(15S); abstr 3523.
105. Goldberg J, Demetri G, Choy E, et al. Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol 2009; 27(15S): abstr 10502.
106. Laux I, Goldman J, Just R, et al. Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. J Clin Oncol 2009; 27(15S); abstr 3549)
107. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-32.
108. Qian F, Engst S, Yamaguchi K, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009; 69(20): 8009-16.
109. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008; 17(7): 997-1011.
110. Eder J, Heath E, Appleman L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I, vol. 25, no. 18S: 3526.
111. Srinivasan R, Choueiri T, Vaishampayan U, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 2008; 26(Suppl): abstr 5103.
112. Salgia R, Sherman S, Hong D, et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 2008; 26(Suppl): Abstr 3522.
113. De Groot J, Prados M, Urquhart T, et al. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol 2009; 27(15S): abstr 2047).
114. Kollmannsberger C, Hurwitz H, Vlahovic G, et al. Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101). J Clin Oncol 2009; 27(Suppl): Abstr e14525.
115. Hong D, LoRusso P, Kurzrock R, et al. Phase I study of MGCD265 administered intermittently to patients with advanced malignancies (Study 265-102). J Clin Oncol 2009; 27(Suppl): Abstr e14516.
116. Camacho L, Moulder S, LoRusso P, et al. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. J Clin Oncol 2008; 26(Suppl): Abstr 14657.
117. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human antihepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007; 13(22 Pt 1): 6735-42.
118. Gordon M, Mendelson D, Sweeney C, et al. Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I, vol. 25, no. 18S: 3551.
119. Rosen P, Sweeney C, Park D, et al. AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors. J Clin Oncol 2008; 26(Suppl): abstr 3570.
120. Reardon D, Cloughsey T, Raizer J, et al. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol 2008; 26(Suppl): abstr 2051.
121. Merchant M, Zhang Y, Su Y, et al. Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors. AACR Meeting Abstracts 2008; 2008: 1336
122. Merchant M, Zhang Y, Su Y. MetMab significantly enhances antitumor activity of anti-VEGF and/or erlotinib in several animal tumor models. 20th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2008; Geneva (Switzerland): Abstr 556.
123. Salgia R, Peterson A, Eppler S. A Phase I, open-label, dose escalation study of the safety and pharmacology of MetMAb, A monovalent antagonist antibody to the recetor c-Met, administered IV in patients with locally advanced or metastatic solid tumors. 20th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2008; Geneva (Switzerland): Abstr 411.
124. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003; 100(22): 12718-23.
125. Yap T, Lolkema M, Tunariu N, et al. Pharmacokinetic and pharmacodynamic Phase I trial of ARQ 197 incorporating dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition. Eur J Cancer Suppl 2009; 7(2): 121.
126. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995; 55(5): 1129-38.
127. Rees H, Williamson D, Papanastasiou A, et al. The MET receptor tyrosine kinase contributes to invasive tumor growth in rhabdomyosarcomas. Growth Factors 2006; 24(3): 197-208.
128. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997; 57(23): 5391-8.
129. Hecht M, Papoutsi M, Tran HD, Wilting J, Schweigerer L. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res 2004; 64(17): 6109-18.
130. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics. J Mol Med 2007; 85(5): 427-36.
131. Kermorgant S, Parker PJ. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 2008; 182(5): 855-63.
132. Gual P, Giordano S, Williams TA, Rocchi S, Van Obberghen E, Comoglio PM. Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 2000; 19(12): 1509-18.
133. Bertotti A, Comoglio PM, Trusolino L. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorageindependent growth. J Cell Biol 2006; 175(6): 993-1003.
134. Lamorte L, Kamikura DM, Park M. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein. Oncogene 2000; 19(52): 5973-81.